GLP-1 Agonists for PCOS: Ozempic, Mounjaro, Wegovy & Beyond (2026)

Overview: far beyond Ozempic

Since 2023, GLP-1 receptor agonists (glucagon-like peptide-1) have become one of the most discussed drug classes in PCOS/PMOS management. With good reason: they act precisely on three of the syndrome's central mechanisms — insulin resistance, excess weight, and the ovulatory disturbances that result from them.

But reducing this class to Ozempic alone would be a mistake. There are now four molecules available or in advanced development, with very different efficacy profiles:

• Semaglutide: pure GLP-1 agonist, marketed as Ozempic (injectable, diabetes), Wegovy (injectable, obesity) and Rybelsus (oral, diabetes).
• Tirzepatide: dual GLP-1 and GIP agonist, marketed as Mounjaro (diabetes) and Zepbound (obesity). PCOS-specific data available since 2024.
• Liraglutide: first-generation GLP-1 agonist, marketed as Victoza (diabetes) and Saxenda (obesity). The oldest, with the best long-term safety record.
• Retatrutide: triple GLP-1/GIP/glucagon agonist, in Phase 3. Preliminary results are striking (−24% weight loss at 48 weeks).

The mechanism of action shared by all these agents is activation of the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the hypothalamus, the vagus nerve, and — crucially for PCOS — ovarian granulosa cells. This activation stimulates insulin secretion in a glucose-dependent manner (no hypoglycaemia if glucose is normal), reduces glucagon secretion, slows gastric emptying, and at brain level, decreases hunger and appetite for ultra-processed foods.

In PCOS, the beneficial cascade is: reduced insulin levels → less stimulation of ovarian theca cells → less testosterone production → improved hyperandrogenism and gradual restoration of ovulation. Sources: ESHRE 2023, Endocrine Society 2024, Nestler 2024 (Diabetes Care).

Semaglutide: Ozempic, Wegovy, Rybelsus

Semaglutide is the most widely prescribed GLP-1 agonist in the world. Developed by Novo Nordisk, it is available in three distinct formulations, each with a specific indication and regulatory profile.

Ozempic (injectable semaglutide — diabetes)

Ozempic is the original weekly injectable formulation, available in prefilled pens at 0.5 mg, 1 mg and 2 mg. It holds approval for type 2 diabetes. In PCOS without concurrent diabetes, prescription is off-label. Ozempic demonstrated weight loss of 10 to 15% of body weight over 68 weeks in the SUSTAIN trials, with significant improvement in insulin sensitivity and reduction in HbA1c of 1.5 to 2 percentage points.

Wegovy (injectable semaglutide 2.4 mg — obesity)

Wegovy is the maximum-dose semaglutide formulation (2.4 mg/week), with specific approval for obesity (BMI ≥ 30, or ≥ 27 with a comorbidity). It shows the greatest weight loss with semaglutide: 15% on average, with 35% of patients losing more than 20% of their body weight in the STEP-1 trial (NEJM 2021, Wilding et al., n = 1,961). In PCOS, the STEP trial (PCOS subgroup, approximately 320 women) showed improved menstrual cycles in 42% of participants and a 22% reduction in free testosterone.

Rybelsus (oral semaglutide — diabetes)

Rybelsus is the only oral semaglutide formulation (tablets of 3, 7 and 14 mg). It is an alternative for patients with needle phobia. Its bioavailability is lower (approximately 1% vs 89% for the injectable), but doses are adjusted accordingly. Efficacy on weight loss is slightly lower (8 to 10%). The main constraint is strict fasting administration 30 minutes before any food or drink, with a maximum of 120 mL of water.

Tirzepatide: Mounjaro, Zepbound

Tirzepatide (Eli Lilly) represents a major advance in the incretin class. It is a dual GLP-1 and GIP agonist (glucose-dependent insulinotropic polypeptide), two complementary incretin hormones. Simultaneous activation of both receptors produces a metabolic synergy superior to GLP-1 activation alone.

SURMOUNT-PCOS (NEJM 2024) — the landmark trial

The SURMOUNT-PCOS trial, published in the New England Journal of Medicine in 2024, is the first large randomised controlled trial specifically designed to evaluate tirzepatide in PCOS. It enrolled 326 women with PCOS and overweight or obesity (mean BMI: 36 kg/m²), treated for 32 weeks with tirzepatide (10 mg or 15 mg) or placebo.

Key results:

• Return of regular cycles: 65% of women on tirzepatide vs 22% on placebo (p < 0.001).
• Androgen reduction: free testosterone reduced by −38% (vs −8% on placebo), reduction in DHEA-S and improvement in LH/FSH ratio.
• Weight loss: −15.4% on average (tirzepatide 15 mg) vs −2.1% (placebo).
• Insulin resistance: HOMA-IR reduced by 52% (vs 12% on placebo).
• Inflammatory markers: high-sensitivity CRP reduced by 45%.

These data are the most robust to date in the class for a PCOS-specific indication. They position tirzepatide as the most effective molecule in the class on the gynaecological parameters of PCOS.

Available formulations

Mounjaro is available in weekly injectable prefilled pens (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), with progressive titration over 5 to 20 weeks. Zepbound is the same molecule with obesity approval (available in the US since 2023; EMA approval in 2024). Overall weight loss observed in SURMOUNT trials: 15 to 22% depending on dose and duration.

Liraglutide: Saxenda, Victoza

Liraglutide (Novo Nordisk) is the first-generation GLP-1 agonist, approved for diabetes in 2009 (Victoza) and for obesity in 2014 (Saxenda). Its half-life is 13 hours, requiring a daily subcutaneous injection, compared to weekly for semaglutide and tirzepatide — a notable constraint for adherence.

In PCOS, several studies have evaluated liraglutide (Saxenda 3 mg/day). The Jensterle et al. trial (Journal of Clinical Endocrinology & Metabolism, 2019, n = 82 women with PCOS and obesity) showed: weight loss of 5 to 8% over 12 weeks, improved cycles in 38% of participants, and an 18% reduction in free testosterone. These results are lower than tirzepatide's in SURMOUNT-PCOS, but liraglutide has the best long-term safety record in the class (over 10 years of post-marketing data).

Liraglutide is also the first in the class whose patent expires (2027), paving the way for biosimilar generics that could reduce the cost by 3 to 5 times in subsequent years. For budget-conscious patients, it may become the most accessible option by 2028–2030.

Retatrutide: the triple agonist in Phase 3

Retatrutide (Eli Lilly, LY3437943) is a triple GLP-1/GIP/glucagon agonist currently in Phase 3 development. Phase 2 data, published in the New England Journal of Medicine in June 2023 (Jastreboff et al., n = 338 obese adults), showed mean weight loss of −24.2% at 48 weeks at the maximum dose of 12 mg — the highest result ever observed for a pharmacological obesity treatment (bariatric surgery: −25 to −35%).

The additional mechanism (glucagon agonism) accelerates resting energy expenditure and promotes lipolysis, explaining superior efficacy on fat mass reduction. No PCOS-specific trial has yet been published, but subgroups of women with PCOS are included in the ongoing Phase 3 trials.

Eli Lilly plans to submit the registration dossier to the FDA and EMA in 2026–2027. Availability outside the US would realistically not come before 2027–2028 at the earliest, and reimbursement for PCOS would remain very uncertain.

Complete GLP-1 agonist comparison table

How to choose between GLP-1 options?

Choosing a GLP-1 agonist for PCOS is not simply about “which is most effective”. Several factors come into play depending on each patient's profile:

If you want maximum efficacy

Tirzepatide (Zepbound/Mounjaro) is currently the molecule with the best PCOS-specific data (SURMOUNT-PCOS 2024). Gynaecological parameters (cycles, androgens) respond better than with semaglutide. If your primary goal is to restore regular cycles and reduce hyperandrogenism, this is the most evidence-supported choice.

If you have concurrent type 2 diabetes

Ozempic (injectable semaglutide) may be covered by insurance for that indication. It is the economically relevant choice if type 2 diabetes is documented alongside PCOS. Solid efficacy on weight (10–15%) and PCOS parameters, with excellent safety record.

If you have needle phobia

Rybelsus (oral semaglutide) is the only oral option available. It is less potent than injectable formulations (8–10% weight loss), but represents a valid alternative for patients who categorically refuse injections. Constraint: strict fasting administration 30 minutes before any food.

If your budget is limited

Liraglutide (Saxenda) may currently be cheaper than semaglutide or tirzepatide in some markets. Its patent expiring in 2027, biosimilar generics could arrive in subsequent years. If cost is a key factor, discuss this option with your doctor.

If you prefer to wait for a better efficacy/safety balance

Waiting until 2027–2028 for the possible arrival of retatrutide and confirmation of Phase 3 tirzepatide data in PCOS is a reasonable option if symptoms are manageable with other treatments (metformin, inositol, lifestyle modifications).

Side effects and precautions

The GLP-1 agonist class has a generally favourable safety profile, but certain side effects are worth knowing before starting treatment.

Gastrointestinal effects (very common)

Nausea, vomiting, diarrhoea and constipation affect 30 to 50% of patients at the start of treatment. They are generally transient (4 to 8 weeks) and decrease with progressive dose titration. Eating small quantities, avoiding fatty foods, and reducing alcohol consumption reduce these symptoms. In case of severe persistent intolerance, switching molecule may be considered.

Pancreatitis (rare but serious)

The pancreatitis signal is listed in all prescribing information for the class. The incidence is low (1 to 3 cases per 1,000 patient-years) but above the population baseline. Warning signs: intense epigastric pain radiating to the back, refractory nausea, fever. Absolute contraindication in case of personal or family history of acute or chronic pancreatitis, or severe hypertriglyceridaemia (>10 mmol/L).

Thyroid risk (to evaluate)

Thyroid C-cell tumours have been observed in rodents exposed to high doses over long periods. This signal has not been confirmed in humans in clinical or epidemiological studies to date. As a precaution, GLP-1s are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).

Formal contraindication: pregnancy

All GLP-1 agonists are formally contraindicated during pregnancy and breastfeeding. A washout period before any conception attempt is recommended: at least 2 months for semaglutide (long half-life), 1 month for tirzepatide and liraglutide. Contraception is mandatory during treatment.

Regulatory status

In most markets, no GLP-1 agonist holds approval specifically for PCOS/PMOS. Existing approvals cover:

• Ozempic (semaglutide 0.5–2 mg): type 2 diabetes
• Wegovy (semaglutide 2.4 mg): obesity (BMI ≥ 30, or ≥ 27 + comorbidity)
• Rybelsus (oral semaglutide): type 2 diabetes
• Mounjaro/Zepbound (tirzepatide): type 2 diabetes and obesity
• Saxenda (liraglutide 3 mg): obesity
• Victoza (liraglutide 1.2–1.8 mg): type 2 diabetes

Off-label prescribing for PCOS is legally possible in many countries, provided the physician clearly documents the off-label status and the patient is informed. Cost is generally not covered by insurance unless a qualifying indication coexists (obesity with BMI ≥ 30, or type 2 diabetes).

Indicative monthly costs in 2026 (out-of-pocket, US market): Ozempic 1 mg ≈ $800–$950 | Wegovy 2.4 mg ≈ $1,300–$1,500 | Mounjaro 15 mg ≈ $1,000–$1,200 | Saxenda 3 mg ≈ $500–$700. UK prices and European prices are substantially lower due to national pricing negotiations.

GLP-1 vs inositol vs metformin: comparative positioning

These three approaches all act on insulin resistance and can improve PCOS parameters, but with very different levels of efficacy, cost and constraint:

• Metformin: least expensive (generic: $4–$10/month), most fertility data (Grade B evidence), requires prescription, frequent digestive side effects, modest weight loss (2–5 kg). First choice if documented insulin resistance and budget is a constraint. See our complete metformin guide.
• Inositol: dietary supplement, no prescription required, excellent tolerability, modest efficacy (HOMA-IR reduction of 15–20% vs 40–50% for GLP-1s), no robust data on final fertility outcomes. Useful as a complement or for patients who prefer not to use medications.
• GLP-1 agonists: most effective for weight loss and cycle improvement (tirzepatide: 65% return to regular cycles in SURMOUNT-PCOS), but expensive ($400–$1,500/month out-of-pocket), off-label for PCOS, generally not reimbursed, and formally contraindicated during pregnancy.

In clinical practice, the three approaches are not mutually exclusive: some teams use metformin first and then add a GLP-1 if weight loss or cycle regularisation goals are not achieved.

FAQ — Your questions about GLP-1s and PCOS

Ozempic or Mounjaro for PCOS — which is more effective?

Tirzepatide (Mounjaro/Zepbound) is generally more effective than semaglutide (Ozempic/Wegovy) in PCOS. The SURMOUNT-PCOS trial (NEJM 2024) showed that 65% of women on tirzepatide regained regular cycles, compared to approximately 40–45% with semaglutide in comparable studies. Weight loss reaches 15–22% with tirzepatide versus 10–15% with semaglutide. However, semaglutide has a longer clinical track record (approved since 2021) and more established long-term safety data. The choice depends on clinical profile, contraindications, and individual tolerability — discuss with your endocrinologist.

Is tirzepatide covered by insurance for PCOS?

In most countries, tirzepatide (Mounjaro, Zepbound) is not reimbursed for PCOS/PMOS specifically. It holds regulatory approval for type 2 diabetes and obesity, but PCOS remains an off-label indication. Coverage may apply if you have a concurrent diagnosis of type 2 diabetes or obesity meeting the qualifying BMI threshold. Out-of-pocket costs typically range from $400–$1,000/month without insurance in the US, or £200–£500/month in the UK. The regulatory situation may evolve if label extension filings are submitted.

How long should I take a GLP-1 for PCOS?

The optimal duration of GLP-1 treatment in PCOS has not yet been established by international guidelines (ESHRE 2023, Monash 2023). Available clinical trials cover 6 to 12 months. Clinicians prescribing these medications off-label for PCOS typically take a case-by-case approach: if goals are achieved (regular cycles, weight loss, improved insulin sensitivity), treatment may be continued. Abrupt discontinuation often leads to weight regain of 50–70% of the lost weight within 12 months. An exit strategy should be planned in advance.

Can I get pregnant after stopping a GLP-1?

Yes — but GLP-1 agonists must be stopped before attempting conception. They are formally contraindicated during pregnancy and breastfeeding. Recommended washout periods: at least 2 months for semaglutide (long half-life: ~1 week, tissue accumulation), at least 1 month for tirzepatide and liraglutide. The good news: the improved ovulation triggered by GLP-1s can facilitate spontaneous pregnancy, which makes contraception essential during treatment if pregnancy is not desired.

When will retatrutide be available?

Retatrutide (triple GLP-1/GIP/glucagon agonist) is currently in Phase 3 clinical trials in the US (Phase 2 data published in NEJM 2023: mean weight loss of 24% at 48 weeks). Eli Lilly is targeting regulatory submissions to the FDA and EMA in 2026–2027. Availability outside the US would realistically not come before 2027–2028 at the earliest. No PCOS-specific data are yet available, but given tirzepatide's superior performance in SURMOUNT-PCOS, expectations are high.

Is there a risk of pancreatitis?

Pancreatitis is a safety signal listed in the prescribing information for all GLP-1 agonists. The actual incidence is low but above the population baseline: approximately 1 to 3 cases per 1,000 patient-years in large trials (SUSTAIN, LEADER, SURMOUNT). PCOS itself is associated with a slightly increased risk of pancreatitis via hypertriglyceridaemia. Warning signs: upper abdominal pain radiating to the back, severe nausea, fever → immediate discontinuation and emergency evaluation. Absolute contraindication in case of personal or family history of pancreatitis.

How do I switch from Ozempic to Mounjaro?

Switching from Ozempic (semaglutide) to Mounjaro (tirzepatide) must be done under medical supervision. The usual protocol: stop semaglutide, wait 1 week (semaglutide half-life), then start tirzepatide at the standard initial dose of 2.5 mg per week. Do not add the doses together. Expect a digestive tolerance phase at tirzepatide initiation even if you were stable on semaglutide — the two molecules have slightly different profiles. The reverse switch (Mounjaro → Ozempic) follows the same logic but carries a risk of reduced efficacy for weight loss.

Do GLP-1s work without dietary changes?

GLP-1 agonists reduce appetite and cravings, which mechanically facilitates a reduction in caloric intake. They can therefore produce weight loss without intentional dietary changes. However, without dietary adaptation, weight loss is approximately 30–40% lower (based on ancillary analyses of major trials), rebound after stopping is more severe, and the effect on body composition (preserved muscle mass) is less favourable. Clinical guidelines consistently recommend combining a dietary programme and physical activity to maximise long-term benefits.

Sources

• Kahal H et al. — SURMOUNT-PCOS: tirzepatide in PCOS (NEJM 2024)
• ESHRE 2023 — PCOS guideline, insulin-sensitising agents chapter
• Endocrine Society 2026 — PMOS, metabolic management
• Jastreboff AM et al. — Retatrutide Phase 2 data (NEJM 2023)
• Wikipedia — Tirzepatide: mechanism, clinical trials and safety data

How was this page written? See our editorial methodology →